Session » Epidemiology and Public Health Poster I: Comorbidities and Outcomes of Systemic Inflammatory Diseases

Date: Sunday, November 8, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 57

Age, Gender, Racial and Comorbidity Differences Among Systemic Lupus Erythematosus Patients Hospitalized with Ischemic Stroke Compared to the General Population: A Nationwide Analysis

9:00AM-11:00AM: Abstract Number: 33

Analysis of Incidence Rates of Pulmonary Embolism in the Rheumatoid Arthritis Population Compared with the Non-Rheumatoid Arthritis Population

9:00AM-11:00AM: Abstract Number: 53

Associations Between Race and Income Disparity on Morbidity in Juvenile Dermatomyositis

9:00AM-11:00AM: Abstract Number: 58

Attribution of Cause of End-Stage Renal Disease Among Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 25

Attrition and Participant Characteristics in a Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 39

Baseline Obesity and Subsequent Weight Loss Are Independently Associated with Cardiovascular Mortality in Established Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 37

Cardiovascular Disease in Immune-Mediated Inflammatory Diseases: Cross Sectional Analysis of the Influence of Demographic and Traditional Cardiovascular Risk Factors

9:00AM-11:00AM: Abstract Number: 50

Characteristics and Outcomes Associated with Early Corticosteroid Use in a Large Multicenter Canadian RA Cohort

9:00AM-11:00AM: Abstract Number: 30

Complications of Inflammatory Arthritis in First Nations and Non-First Nations Populations of Alberta, Canada

9:00AM-11:00AM: Abstract Number: 45

Contributions of Social Determinants of Health on Probability of Remission in Early and Established Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 29

Development of Multimorbidity in Patients with Newly Diagnosed Rheumatoid Arthritis – a Population-Based Study

9:00AM-11:00AM: Abstract Number: 42

Does the Risk of Mortality in Patients with RA Change over Time or Disease Duration?

9:00AM-11:00AM: Abstract Number: 49

Dose Relationship Between Oral Glucocorticoids and TNF Inhibitors and the Risk of Hospitalized Infectious Events Among Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 46

Feasibility Study of Smartphone Data Collection for Cloudy with a Chance of Pain: Sustained Engagement for Daily Self-Reporting of Disease Severity in Rheumatoid Arthritis over Two Months

9:00AM-11:00AM: Abstract Number: 26

Higher Scores of Women Compared to Men for Most Clinical Measures of Rheumatoid Arthritis (RA) Status: Greater Differences for Patient Self-Report Scores Than for Rheumatologist Estimates: A Cross-Sectional 3 Center Study from Routine Care

9:00AM-11:00AM: Abstract Number: 54

Impact of Age at Disease Diagnosis on Clinical Manifestations, Disease Activity, and Outcomes in Patients with Systemic Lupus Erythematosus: Single-Center Prospective Cohort Study

9:00AM-11:00AM: Abstract Number: 38

Impact of Obesity on the Disease Course of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 55

Increased Incidence of Tuberculosis Among Systemic Lupus Erythematous Patients – Should Tuberculosis Screening at Diagnosis be the Next Step?

9:00AM-11:00AM: Abstract Number: 40

Increased Mortality in Indigenous North Americans Persons with Rheumatoid Arthritis Is Partially Explained By Psychiatric and Physical Comorbidity: a Population Based Study

9:00AM-11:00AM: Abstract Number: 24

Investigating the Role of Vitamin D in the Transition to Systemic Lupus Erythematosus in Individuals at Risk for the Disease

9:00AM-11:00AM: Abstract Number: 60

Mortality of Systemic Lupus Erythematosus in Puerto Rico Assessed By Multiple-Cause-of-Death Analysis

9:00AM-11:00AM: Abstract Number: 51

Oral Glucocorticoid Use Is Associated with Osteonecrosis in Adults with Chronic Inflammatory Diseases but Not in Children: A Population-Based Cohort Study

9:00AM-11:00AM: Abstract Number: 62

Patient Perception of Disease Burden in Diffuse Cutaneous Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 48

Polypharmacy Is a Predictor of Hospitalisation in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 61

Predictors of Mortality Among Patients with Sarcoidosis: A Population-Based Study

9:00AM-11:00AM: Abstract Number: 43

Prevalence and Relevance of Depressive Symptoms in Patients with Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 35

Rheumatoid Arthritis As a Risk Factor for Cardiovascular Events Following Hospitalized Pneumonia; A Population-Based Cohort Study

9:00AM-11:00AM: Abstract Number: 32

Risk for Lung Cancer in RA and Different RA Phenotypes: Results from a Population-Based Case-Control Study

9:00AM-11:00AM: Abstract Number: 31

Risk of Chronic Obstructive Pulmonary Disease in Rheumatoid Arthritis: A Population Based Cohort Study

9:00AM-11:00AM: Abstract Number: 27

Self-Reported Sedentary Behavior in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 28

The Decrease over Time of Orthopaedic Surgery in Patients with Rheumatoid Arthritis Is Mainly Due to Reduced Rates Among Those with Rheumatoid Factor Positive Disease – Results from a Well Defined Area

9:00AM-11:00AM: Abstract Number: 34

The Impact of Cardiovascular and Lung Disorder Morbidities on Physical Activity in People with Inflammatory Arthritis Compared to the General Population in the UK

9:00AM-11:00AM: Abstract Number: 36

The Incidence of Cardiovascular Events in Patients with Rheumatoid Arthritis: a 15 Years Observational Cohort Study

9:00AM-11:00AM: Abstract Number: 44

The Prevalence of Depression and Anxiety in a Cross-Section of Rheumatological Conditions

9:00AM-11:00AM: Abstract Number: 41

Trends in Non-Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis: Is There Room for Improvement?

9:00AM-11:00AM: Abstract Number: 47

Use of Social Media Data for Comparative Effectiveness and Safety Research: An Example from Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 56

Utilizing City-Wide Electronic Health Record Data to Assess Care Fragmentation in Patients with Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 52

Validity of Simplified Ankylosing Spondylitis Disease Activity Scores (SASDAS) in Indian As Patients

9:00AM-11:00AM: Abstract Number: 59

Variation in Heart Failure Hospitalizations Among U.S. Medicaid Recipients with SLE 2000-2010, By Race and Ethnicity

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].